This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-12 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== Feature films === Phang's debut feature film that she directed and wrote was entitled Half-Life (2008) and it starred Sanoe Lake, Julia Nickson-Soul, Leonardo Nam, James Eckhouse, Susan Ruttan and Alexander Agate. The film premiered at the 2008 Sundance Film Festival in the New Frontiers section, and also screened at the Gen Art Film Festival (where it won a Best Feature award), the San Francisco International Asian American Film Festival (where it won a Best Narrative award), the Asian American International Film Festival (where Phang won the "Emerging Director Award"), the Fairy Tales International Gay & Lesbian Film Festival (where it won the Visionary Award), the Tokyo International Film Festival (where it was in-competition and was nominated for the Tokyo Grand Prix), the Mannheim-Heidelberg International Film Festival (where it was also in competition and nominated for the Main Award), and the International Women's Film Festival in Seoul, Korea (where it was opening night film). The film received a limited theatrical release on December 1, 2009. After Half life, Phang's follow-up project was, Look For Water, and Crazy Beats Strong Every Time. Phang received a grant from the Sundance Institute Cinereach Grant, the Sundance Annenberg Feature Film Fellowship, and the Tribeca Film Festival to support these developments. Phang's follow up film that she directed, wrote and edited was Advantageous (2015), which was based on her award-winning short film of the same name. The film starred Jacqueline Kim, Ken Jeong, James Urbaniak, Freya Adams and Samantha Kim.
Blue Shift was announced in the second quarter of 2000 as part of an upcoming Dreamcast port of Half-Life. While the port was developed by Captivation Digital Laboratories, Blue Shift was developed by Gearbox Software, who also developed the first Half-Life expansion, Opposing Force. The game had the working title Half-Life: Guard Duty; publisher Sierra Entertainment announced the name Blue Shift on August 30, 2000. As with Opposing Force, the title has a double meaning, referring to both the blue shift light phenomenon and the name of Barney's shift. The Dreamcast port would include higher detail models and textures that were double the polygon count of Valve's original Half-Life models. At the European Computer Trade Show in September 2000, information about Blue Shift's story and development direction was revealed, along with a release date of November 1, 2000, for the Dreamcast version of Half-Life. The port was delayed by Sierra to ensure the "high expectations of consumers" were met, anticipating release by the end of the year. On March 29, 2001, Sierra announced that Blue Shift would also be released for Windows as a standalone game that would not require the original Half-Life to run. The new models developed for the Dreamcast version would also be included in the PC version as the Half-Life High Definition pack, and could be applied to Half-Life and Opposing Force. At the E3 2001, Gearbox announced that Blue Shift was complete and exhibited a playable version. It was released on June 12, 2001, in North America, and on June 15 in Europe.
=== Major hormones === Neurokinin B (a tachykinin peptide) and kisspeptin (a neuropeptide), both present in KNDy neurons of the hypothalamus, are critical parts of the control system that switches on the release of GnRH at the start of puberty. GnRH (gonadotropin-releasing hormone) is a peptide hormone released from the hypothalamus which stimulates gonadotrope cells of the anterior pituitary. LH (luteinizing hormone) is a larger protein hormone secreted into the general circulation by gonadotrope cells of the anterior pituitary gland. The main target cells of LH are the Leydig cells of testes and the theca cells of the ovaries. LH secretion changes more dramatically with the initiation of puberty than FSH, as LH levels increase about 25-fold with the onset of puberty, compared with the 2.5-fold increase of FSH. FSH (follicle stimulating hormone) is another protein hormone secreted into the general circulation by the gonadotrope cells of the anterior pituitary. The main target cells of FSH are the ovarian follicles and the Sertoli cells and spermatogenic tissue of the testes. Testosterone is a steroid hormone produced primarily by the Leydig cells of the testes, and in lesser amounts by the theca cells of the ovaries and the adrenal cortex. Testosterone is the primary mammalian androgen and the "original" anabolic steroid. It acts on androgen receptors in responsive tissue throughout the body. Estradiol is a steroid hormone produced by aromatization of testosterone. Estradiol is the principal human estrogen and acts on estrogen receptors throughout the body.
=== Discovery of radioactive recoil === Harriet Brooks observed a radioactive recoil in 1904, but interpreted it wrongly. Hahn and Meitner succeeded in demonstrating the radioactive recoil incident to alpha particle emission and interpreted it correctly. Hahn pursued a report by Stefan Meyer and Egon Schweidler of a decay product of actinium with a half-life of about 11.8 days. Hahn determined that it was actinium X (radium-223). He also discovered that at the moment when a radioactinium (thorium-227) atom emits an alpha particle, it does so with great force, and the actinium X experiences a recoil. This is enough to free it from chemical bonds, and it has a positive charge, and can be collected at a negative electrode. Hahn was thinking only of actinium, but on reading his paper, Meitner told him that he had found a new way of detecting radioactive substances. They set up some tests, and soon found actinium C'' (thallium-207) and thorium C'' (thallium-208). The physicist Walther Gerlach described radioactive recoil as "a profoundly significant discovery in physics with far-reaching consequences".
Sources: en.wikipedia.org
Carbohydrates: 5 to 15% of the energy consumed Protein: 20 to 30% Fats: 0 to 3% Raw celery and grapefruit are often claimed to have negative caloric balance (requiring more energy to digest than recovered from the food), with the assumption being that the thermic effect exceeds the low caloric content due to the high fibre matrix that must be unraveled to access their carbohydrates. However, there has been no research carried out to test this hypothesis and a significant amount of the thermic effect depends on the insulin sensitivity of the individual, with more insulin-sensitive individuals showing a significant TEF while individuals with increasing resistance have negligible to zero effects. The Functional Food Centre at Oxford Brookes University conducted a study into the effects of chilli peppers and medium-chain triglycerides (MCT) on Diet Induced Thermogenesis (DIT). They concluded that "adding chilli and MCT to meals increases DIT by over 50% which over time may accumulate to help induce weight loss and prevent weight gain or regain". Australia's Human Nutrition conducted a study on the effect of meal content in lean women's diets on the thermic effect of food and found that the inclusion of an ingredient containing increased soluble fibre and amylose did not reduce spontaneous food intake but rather was associated with higher subsequent energy intakes despite its reduced glycaemic and insulinemic effects.
==== Albums ==== Butterfly Love (Boner Records, 1989) Lurch (Boner Records, 1990) Tulip (Boner Records, 1990) The Miracle of Sound in Motion (Boner Records, 1993) Your Choice Live Series 019 (Your Choice Records, 1993) Best of Steel Pole Bathtub (Sento, 1993) Scars from Falling Down (Slash/London, 1995) Unlistenable (Zero to One, 2002)
== Function == The compressive forces applied to the foot are distributed along five rays, three medial (side of big toe) and two lateral (side of little toe). The lateral rays stretch over the cuboid bone to the heel bone and the medial rays over the three cuneiform bones and the navicular bone to the ankle bone. Because the ankle bone is placed over the heel bone, these rays are adjacent near the toes but overriding near the heel, and together they form the arches of the foot that are optimized to distributed compressive forces across an uneven terrain. In this context the heel thus forms the posterior point of support that together with the balls of the large and little toes bear the brunt of the loads.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.